Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo

Overview

Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo

Full Title of Study: “Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: July 15, 2020

Detailed Description

This is a cross-sectional study to estimate the prevalence of antibodies against SARS-CoV-2 is different population subgroups in the State of São Paulo

Interventions

  • Diagnostic Test: Serological test
    • IgM and IgG for SARS-CoV-2
  • Diagnostic Test: Nasopharyngeal Swab
    • PCR for SARS-CoV-2
  • Diagnostic Test: Oropharyngeal Swab
    • PCR for SARS-CoV-2

Arms, Groups and Cohorts

  • HC-USP
    • Home contacts of health professionals diagnosed with COVID-19 at the Hospital of Clínic of Medicine School of the University of São Paulo
  • CORAS
    • Refugees living in the city of São Paulo
  • Hemocenter
    • Blood Donors of the Pró-Sangue Hemocenter Foundation of São Paulo
  • CPP – Butantan Penitentiary Progression Center
    • Participants of the CPP – Butantan Penitentiary Progression Center
  • CHSP – Penitentiary System Hospital Center
    • Participants of the CHSP – Penitentiary System Hospital Center
  • SABE (Health, Wellness and Aging)
    • Participants of the SABE Project (Health, Wellness and Aging)
  • ILPI – Long-Term Care Institution for the Elderly
    • Residents of the Long-Term Care Institution for the Elderly of Botucatu
  • ICR-USP – Children’s Institute of HCFMUSP
    • Home contacts of children and adolescents diagnosed with COVID-19, attended at the Children’s Institute of HCFMUSP

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of antibodies against SARS-CoV-2 through serological testing
    • Time Frame: 1 month
    • IgM and IgG antibodies against SARS-CoV-2
  • Frequency of participants with a positive RT-PCR test result for SARS-CoV-2
    • Time Frame: 1 month
    • Positive RT-PCR test result for SARS-CoV-2

Participating in This Clinical Trial

Inclusion Criteria

  • All potential volunteers invited to participate in the study. Exclusion Criteria:

  • All potential eligible participants, but who do not show interest in participating in the study.

Gender Eligibility: All

Minimum Age: 6 Months

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Butantan Institute
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alexander R Precioso, MD, PhD, Study Chair, Instituto butantan

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.